Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NO-modified autologous tumor vaccine
- Development stage
- Preclinical
- Lead developer
- The Lundquist Institute
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Administration
- Subcutaneous
01
Overview
NO-modified autologous tumor vaccine is an experimental cancer immunotherapy consisting of autologous tumor cells treated with a nitric oxide (NO) donor. The vaccine is prepared by culturing tumor cells (e.g., B16-F0 melanoma) in the presence of a slow-release NO donor, which immuno-sensitizes the cells by regulating apoptosis-related genes and modifying protein structures. The cells are then homogenized into a crude lysate for administration. In preclinical models, this modification has been shown to significantly decrease tumor growth rates and increase survival by promoting a robust therapeutic immune response against cancer cells.
- Other names
- nitric oxide-modified autologous tumor vaccineNO-modified autologous cancer vaccine
02
Targets
Beyond the preview
Go deeper on NO-modified autologous tumor vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NO-modified autologous tumor vaccine.